查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493197

美國骨關節炎注射市場規模、佔有率和趨勢分析報告：按注射劑類型、解剖結構、最終用途和細分市場預測，2024-2030 年

U.S. Osteoarthritis Injectables Market Size, Share & Trends Analysis Report By Injection Type (Hyaluronic Acid Injections, Corticosteroids Injections), By Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 137 Pages | 商品交期: 2-10個工作天內

價格

美國骨關節炎注射劑市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國骨關節炎注射市場預計將達到63億美元，2024年至2030年複合年成長率為6.8%。

這個市場主要是由骨關節炎盛行率的增加和對個人化醫療的高需求所推動的。此外，製藥公司以及研究和學術機構也參與了該國針對 OA 的個人化和細胞治療方法的開發。例如，2023 年 5 月，UCI Health 宣布進行 IMMO1-STEM 的首次人體臨床試驗，這是一種基於細胞的注射療法，用於治療輕度至中度膝骨關節炎患者的肌肉萎縮。

老年人口的增加（更容易患膝骨關節炎）正在推動市場成長。根據 NCBI 2023 年 5 月的報告，由於快速老化和肥胖，預計到 2030 年，骨關節炎患者人數將增加一倍以上，達到 6,700 萬人。此外，超過 50% 的 OA 病例預計發生在 65 歲及以上的年齡層。根據 2024 年 3 月 CDC 支持的 OAAA 研究，約 45% 的 OA 患者年齡超過 65 歲，所有病例中 88% 發生在 45 歲及以上年齡層。在日本，膝關節 OA 的年發生率在 55 歲至 64 歲之間最高。人口老化的高風險會降低工作效率並增加國家的疾病負擔，進而影響整體生產力。

為了控制骨關節炎的症狀並防止其結構性進展，各大製藥公司和研究機構正在積極從事新藥的研發活動，特別是緩解疾病的療法。例如，2024 年 1 月，BioSenic 宣布計劃在 2024 年國際骨關節炎協會 (OARSI) 世界大會上共用JTA-004 3 期研究的事後分析資料。 JTA-004是一種創新的膝關節骨關節炎治療藥物，這項研究表明，單次注射該臨床實驗藥物對於膝關節骨關節炎的嚴重發炎亞型是安全有效的。

此外，研究和學術機構也參與了骨關節炎新治療方法的發展。例如，根據 2023 年 3 月的《科學轉化醫學》報告 GP130，一種臨床實驗藥物可以消除發炎並控制疼痛和僵硬。該藥物現在將在早期臨床試驗中進行測試。此外，2021 年 12 月，Kolon TissueGene, Inc. 宣布美國FDA 已批准啟動 TG-C 治療髖關節 OA 的 2 期臨床試驗。該試驗將評估研究期間疼痛和生活品質的改善。

美國骨關節炎注射市場報告亮點

  • 2023年，玻尿酸（HA）注射領域主導美國市場。 HA 注射療法治療骨關節炎的最新進展引起了人們對基於 HA 的水凝膠療法的關注。
  • 2023年，膝骨關節炎細分市場佔最大市場。這種疾病的日益流行預計將增加老年族群中預防和治療膝骨關節炎的需求，以提高老年人口的生活品質並降低殘疾率。
  • 零售藥房領域預計在預測期內複合年成長率最快。零售藥局充當製造商和醫療保健提供者之間的中間人，大量購買膝骨關節炎注射並儲存起來，直到需要為止。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章美國骨關節炎注射市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國骨關節炎注射劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析

第4章美國骨關節炎注射市場：注射類型估算及趨勢分析

  • 美國骨關節炎注射劑市場：注射型儀表板
  • 美國骨關節炎注射市場：注射品種波動分析
  • 按註入類型分類的收益
  • 玻尿酸注射
  • 皮質類固醇注射
  • 富血小板血漿（PRP）注射
  • 胎盤組織基質 (PTM) 注射
  • 乙醯水楊酸（ASA）注射液
  • 其他

第5章美國骨關節炎注射市場：解剖估算與趨勢分析

  • 美國骨關節炎注射市場：解剖儀表板
  • 美國骨關節炎注射市場：解剖變異分析
  • 解剖學、收益
  • 膝骨關節炎
  • 髖骨關節炎
  • 手骨關節炎
  • 其他

第6章美國骨關節炎注射市場：最終用途估計與趨勢分析

  • 美國骨關節炎注射劑市場：最終用途儀表板
  • 美國骨關節炎注射劑市場：最終用途變化分析
  • 按最終用途分類的收益
  • 醫院藥房
  • 零售藥房
  • 其他

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
  • 公司簡介
    • Anika Therapeutics, Inc.
    • Bioventus.
    • Ferring Pharmaceuticals Inc.
    • Sanofi SA
    • Flexion Therapeutics, Inc.
    • Zimmer Biomet
    • Arthrex, Inc.
    • Royal Biologics
    • Teva Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-264-3

U.S. Osteoarthritis Injectables Market Growth & Trends:

The U.S. osteoarthritis injectables market size is anticipated to reach USD 6.30 billion by 2030 and is expected to expand at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing prevalence of osteoarthritis and high demand for personalized medicine. Moreover, pharmaceutical companies and research & academic institutes are involved in the development of personalized treatment and cell-based therapies for OA in the country. For instance, in May 2023, UCI Health announced the first-in-human clinical trial of its IMMO1-STEM, a cell-derived injectable treatment, to target muscle atrophy in patients with mild to moderate knee osteoarthritis.

Growing geriatric population susceptible to osteoarthritis fuels the growth of the market. According to the NCBI report in May 2023, a rapidly aging population coupled with obesity is expected to more than double the number of people suffering from OA to 67 million by 2030.Moreover, it is expected that more than 50% of OA cases are expected to occur in the age group of 65 and above.According to an OAAA study supported by CDC in March 2024, around 45% of people having OA are 65 & above and 88% of the total cases occur in the age group of 45 & above. The annual incidence of knee OA is highest among people aged 55 to 64 in the country. Such a high risk for geriatric population is affecting overall productivity by reducing work efficiency and increasing the disease burden in the country.

Increase in R&D activities for injectable drug development is boosting the market growth.To manage OA symptoms and prevent its structural progression, key pharmaceutical companies and research institutes are actively involved in R&D activities for the development of novel drugs, especially disease-modifying OA drugs. For instance, in January 2024, BioSenic announced its plans to share the data of post hoc analysis of the phase 3 study of JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024. JTA-004 is an innovative IA treatment for knee OA, and the study showed that a single injection of an investigational drug is safe and effective for the treatment of severe inflammatory subtypes of knee OA.

Furthermore, research and academic institutes are involved in the development of novel treatment options for OA. For instance, in March 2023, according to Science Translational Medicine report GP130, an investigational drug can disrupt inflammation and manage pain & stiffness. The drug will be tested in the upcoming initial phases of clinical trials. Moreover, in December 2021, Kolon TissueGene, Inc. announced that the U.S. FDA allowed it to initiate a Phase 2 clinical trial of TG-C in OA of the hip. The study will assess the pain and quality-of-life improvements during the investigation period.

U.S. Osteoarthritis Injectables Market Report Highlights:

  • In 2023, Hyaluronic Acid (HA) injections segment dominated the U.S. market, owing to recent advancements in HA injection therapy for osteoarthritis focus on HA-based hydrogel therapeutics.
  • Knee osteoarthritis segment held the largest share of the market in 2023.The rising prevalence of the condition is expected to boost the need for the prevention and treatment of knee osteoarthritis in the older population to improve quality of life and decrease disability rates in the elderly population.
  • The retail pharmacies segment is anticipated to witness the fastest CAGR over the forecast period. Retail pharmacies serve as intermediaries between manufacturers and healthcare providers, purchasing osteoarthritis injectables in bulk and storing them until requested.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Injection Type
    • 1.2.2. End-use
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Injection Type
    • 2.2.2. End-use
  • 2.3. Competitive Insights

Chapter 3. U.S. Osteoarthritis Injectables Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of osteoarthritis
      • 3.2.1.2. Growing geriatric population susceptible to osteoarthritis
      • 3.2.1.3. Increase in R&D activities for injectable drug development
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Adoption of other treatment options
      • 3.2.2.2. High cost of treatment
  • 3.3. U.S. Osteoarthritis Injectables Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Pricing Analysis
    • 3.3.3. Pricing Analysis

Chapter 4. U.S. Osteoarthritis Injectables Market: Injection Type Estimates & Trend Analysis

  • 4.1. U.S. Osteoarthritis Injectables Market: Injection Type Dashboard
  • 4.2. U.S. Osteoarthritis Injectables Market: Injection Type Movement Analysis
  • 4.3. U.S. Osteoarthritis Injectables Market Estimates and Forecasts, By Injection Type, Revenue (USD Million)
  • 4.4. Hyaluronic Acid Injections
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Corticosteroid Injections
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Platelet-rich Plasma (PRP) Injections
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Placental Tissue Matrix (PTM) Injections
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Acetylsalicylic Acid (ASA) Injections
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Osteoarthritis Injectables Market: Anatomy Estimates & Trend Analysis

  • 5.1. U.S. Osteoarthritis Injectables Market: Anatomy Dashboard
  • 5.2. U.S. Osteoarthritis Injectables Market: Anatomy Movement Analysis
  • 5.3. U.S. Osteoarthritis Injectables Market Estimates and Forecasts, By Anatomy, Revenue (USD Million)
  • 5.4. Knee Osteoarthritis
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Hip Osteoarthritis
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Hand Osteoarthritis
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Osteoarthritis Injectables Market: End-use Estimates & Trend Analysis

  • 6.1. U.S. Osteoarthritis Injectables Market: End-use Dashboard
  • 6.2. U.S. Osteoarthritis Injectables Market: End-use Movement Analysis
  • 6.3. U.S. Osteoarthritis Injectables Market Estimates and Forecasts, By End-use, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Anika Therapeutics, Inc.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bioventus.
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Ferring Pharmaceuticals Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Sanofi S.A.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Flexion Therapeutics, Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Zimmer Biomet
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Arthrex, Inc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Royal Biologics
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Teva Pharmaceutical Industries Ltd.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 Pipeline analysis, osteoarthritis injectables
  • Table 4 Pricing of key injectable drugs/therapies
  • Table 5 U.S. osteoarthritis injectables market revenue estimates and forecast, by injection type, 2018 - 2030 (USD Million)
  • Table 6 U.S. osteoarthritis injectables market revenue estimates and forecast, by anatomy, 2018 - 2030 (USD Million)
  • Table 7 U.S. osteoarthritis injectables market revenue estimates and forecast, by end use, 2018 - 2030 (USD Million)
  • Table 8 Company market share, 2023
  • Table 9 List of players adopting acquisition strategy
  • Table 10 Key companies undergoing partnership & collaborations.
  • Table 11 Key companies receiving approvals.
  • Table 12 Key companies undertaking other activities.

List of Figures

  • Fig. 1 U.S. osteoarthritis injectables market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Injection type and anatomy segment snapshot
  • Fig. 10 End-use segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market (USD billion)
  • Fig. 13 U.S. osteoarthritis injectables market dynamics
  • Fig. 14 Prevalence of osteoarthritis in the U.S., by type
  • Fig. 15 U.S. population aged 65 and above, by years (Million)
  • Fig. 16 U.S. pharmaceuticals registration details
  • Fig. 17 U.S. drug pricing
  • Fig. 18 U.S. osteoarthritis injectables market: PORTER's analysis
  • Fig. 19 U.S. osteoarthritis injectables market: PESTLE analysis
  • Fig. 20 U.S. osteoarthritis injectables market: Injection type outlook and key takeaways
  • Fig. 21 U.S. osteoarthritis injectables market: Injection type movement analysis
  • Fig. 22 Corticosteroid injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Hyaluronic acid injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Platelet-rich Plasma (PRP) injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Placental Tissue Matrix (PTM) injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Acetylsalicylic Acid (ASA) injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. osteoarthritis injectables market: Anatomy outlook and key takeaways
  • Fig. 29 U.S. osteoarthritis injectables market: Anatomy movement analysis
  • Fig. 30 Knee osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Hip osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Hand osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. osteoarthritis injectables market: End-use outlook and key takeaways
  • Fig. 35 U.S. osteoarthritis injectables market: End-use movement analysis
  • Fig. 36 Hospitals pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Others market estimates and forecast, 2018 - 2030 (USD Million)